ScanWatch FDA approval for release in the United States has finally been granted to Withings.
, by raj, 1 min reading time
Withings has finally gained FDA approval for its ScanWatch hybrid smartwatch and now be sold in the United States.
The ScanWatch was first introduced in Europe in 2020, and it gained CE approval for its ECG and sleep apnea detection.
However, the FDA created a legal roadblock, preventing the product from being sold in the United States. But that's all changed today, and the ScanWatch will be available for purchase in the United States starting in November. There's no news on whether the new ScanWatch Horizon or the less expensive Withings Move ECG will be released.
Because of its combination of excellent data, analysis, sensors, and battery life, the Withings ScanWatch earned a rousing review in its Wareable test, and it's one of our best health smartwatches.
It's a hybrid smartwatch, which means all the smart stuff is concealed beneath an analogue face with real hands, in classic Withings flair.
The ECG feature on the Withings ScanWatch allows you to monitor your heart rhythm for irregularities that might indicate Afib.
It will also monitor your blood oxygen levels and breathing patterns at night, alerting you if you're having moderate or severe apnea episodes.
When the Withings ScanWatch goes on sale, it will cost Rs. 20,935 for the 38mm and Rs. 22,435 for the 42mm. That's a significant discount over the Apple Watch Series 7, and it puts it on par with the Fitbit Sense, which both include ECG.
The oomph factor: Marc Jacobs Riley is here
All for the Pride: Apple will release Pride Edition.
Motiv Ring along with Alexa will assist to find your lost phone